Draft Community Herbal Monograph On Filipendula Ulmaria (L.) Maxim. (= Spiraea Ulmaria (L.)), Herba
o
EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH
25 November 2010
EMA/HMPC/434881/2010
Committee on Herbal Medicinal Products (HMPC)
Community herbal monograph on Filipendula ulmaria (L.) Maxim. (= Spiraea ulmaria (L.)), herba
Draft
Herbal medicinal products; HMPC; Community herbal monographs; traditional use; Filipendula ulmaria (L.) Maxim. (= Spiraea ulmaria (L.)), herba; Filipendulae ulmariae herba; meadowsweet
|
Discussion in Working Party on Community monographs and Community list (MLWP) |
July 2010 November 2010 |
|
Adoption by Committee on Herbal Medicinal Products (HMPC) for release for consultation |
25 November 2010 |
|
End of consultation (deadline for comments). Comments should be provided using this template to hmpc.secretariat@ema.europa.eu |
15 April 2011 |
|
Rediscussion in Working Party on Community monographs and Community list (MLWP) | |
|
Adoption by Committee on Herbal Medicinal Products (HMPC) |
Keywords
|
BG (balgarski): |
LT (lietuviq. kalba): |
|
CS (cestina): nat' tuzebniku jilmového |
LV (latviesu valoda): |
|
DA (dansk): |
MT (malti): |
|
DE (Deutsch): |
NL (nederlands): Moerasspirea |
|
EL (ellinika): |
PL (polski): |
|
EN (English): meadowsweet |
PT (português): |
|
ES (espanol): |
RO (româna): |
|
ET (eesti keel): |
SK (slovencina): |
|
FI (suomi): |
SL (slovenscina): |
|
FR (français): |
SV (svenska): |
|
HU (magyar): |
IS (íslenska): |
|
IT (italiano): |
NO (norsk): |
An agency of the European Union
7 Westferry Circus • Canary Wharf • London E14 4HB • United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7051 E-mail info@ema.europa.eu Website www.ema.europa.eu
© European Medicines Agency, 2011. Reproduction is authorised provided the source is acknowledged.
Community herbal monograph on Filipendula ulmaria (L.) Maxim. (= Spiraea ulmaria (L.)), herba
Name of the medicinal product
To be specified for the individual finished product.
1. Qualitative and quantitative composition1,2
|
Well-established use |
Traditional use |
|
With regard to the registration application of Article 16d(1) of Directive 2001/83/EC as amended Filipendula ulmaria (L.) Maxim. (= Spiraea ulmaria (L.)), herba (meadowsweet) i) Herbal substance Not applicable. ii) Herbal preparations a) Comminuted herbal substance b) Powdered herbal substance |
2. Pharmaceutical form
|
Well-established use |
Traditional use |
|
Comminuted herbal substance as herbal tea for oral use. Powdered herbal substance in solid dosage forms for oral use. The pharmaceutical form should be described by the European Pharmacopoeia full standard term. |
1 The material complies with the Ph. Eur. monograph (ref.: 01/2008:1868 corrected 6.0).
2 The declaration of the active substance(s) for an individual finished product should be in accordance with relevant herbal quality guidance.
3. Clinical particulars
3.1. Therapeutic indications
|
Well-established use |
Traditional use |
|
Indication 1) Traditional herbal medicinal product for the supportive treatment of common cold. Indication 2) Traditional herbal medicinal product for the relief of minor articular pain. The product is a traditional herbal medicinal product for use in specified indications exclusively based upon long-standing use. |
3.2. Posology and method of administration
|
Well-established use |
Traditional use |
|
Posology Adults, Elderly a) Comminuted herbal substance as herbal tea: single dose: 1.5-6 g, as an infusion daily dose: 2-18 g b) Powdered herbal substance: single dose: 250-500 mg daily dose: 250-1500 mg The use in children and adolescents under 18 years of age is not recommended (see section 4.4 'Special warnings and precautions for use'). Duration of use Indication 1) The therapy should start at first signs of common cold. If the symptoms persist longer than 7 days during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted. Indication 2) Not to be used for more than 4 weeks. |
|
Well-established use |
Traditional use |
|
If the symptoms persist during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted. Method of administration Oral use. |
3.3. Contraindications
|
Well-established use |
Traditional use |
|
Hypersensitivity to salicylates. Hypersensitivity to the active substance. |
3.4. Special warnings and precautions for use
|
Well-established use |
Traditional use |
|
The use in children and adolescents under 18 years of age has not been established due to lack of adequate data. Concomitant use with salicylates and other NSAIDs is not recommended without medical advice. Indication 1) If fever exceeds 39°C, persists or is associated with severe headache or if symptoms worsen during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted. Indication 2) The product is not intended to be used in case of acute arthritis as this condition requires medical advice. |
3.5. Interactions with other medicinal products and other forms of interaction
|
Well-established use |
Traditional use |
|
None reported. |
3.6. Pregnancy and lactation
|
Well-established use |
Traditional use |
|
Safety during pregnancy and lactation has not been established. In the absence of sufficient data, the use during pregnancy and lactation is not recommended. |
3.7. Effects on ability to drive and use machines
|
Well-established use |
Traditional use |
|
No studies on the effect on the ability to drive and use machines have been performed. |
3.8. Undesirable effects
|
Well-established use |
Traditional use |
|
None known. If adverse reactions occur, a doctor or a qualified health care practitioner should be consulted. |
3.9. Overdose
|
Well-established use |
Traditional use |
|
No case of overdose has been reported. |
4. Pharmacological properties
4.1. Pharmacodynamic properties
|
Well-established use |
Traditional use |
|
Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended. |
4.2. Pharmacokinetic properties
|
Well-established use |
Traditional use |
|
Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended. |
4.3. Preclinical safety data
Well-established use
Traditional use
|
Well-established use |
Traditional use |
|
Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended, unless necessary for the safe use of the product. Tests on reproductive toxicity, genotoxicity and carcinogenicity have not been performed. |
5. Pharmaceutical particulars
|
Well-established use |
Traditional use |
|
Not applicable. |
6. Date of compilation/last revision
25 November 2010
Page 6/6
Community herbal monograph on Filipendula ulmaria (L.) Maxim. (= Spiraea ulmaria
(L.)), herba
EMA/HMPC/434881/2010